News
DEBUT trial of Buvidal opioid dependence treatment is published in JAMA Open Network.- Camurus AB
Camurus announced the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly Buvidal (buprenorphine depot injections) versus daily sublingual buprenorphine.
Camurus announced the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly Buvidal (buprenorphine depot injections) versus daily sublingual buprenorphine.
A total of 119 patients with opioid dependence were randomized and received treatment in the DEBUT study, conducted at six outpatient clinical sites in Australia. The primary outcome of the study was global treatment satisfaction, as measured by the 14-question Treatment Satisfaction Questionnaire for Medication (TSQM) at the end of the study at week 24. The study met its primary endpoint with a significantly higher TSQM global satisfaction score among participants who received depot injections compared to those who received sublingual buprenorphine (difference, 8.2; 95% CI, 1.7-14.6; P=.01).
Improved outcomes were seen for several secondary outcomes, including a decreased treatment burden and higher quality of life. The safety profile was consistent with the known safety profile of buprenorphine, aside from transient, mild-to-moderate injection site reactions. The data is published in JAM Network Open.
See: "Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine;A Randomized Clinical Trial" Nicholas Lintzeris et al. JAMA Netw Open. 2021;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041.
Condition: Opioid Dependence
Type: drug